Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1800 results
August 2018
-
Embracing big data to understand complex diseases
Researchers discover that networks of proteins circulating in the blood influence the development and progression of chronic diseases.
-
Discovery gives cystic fibrosis researchers new direction
Novartis-Harvard team identifies a new type of cell that is key to the disease.
July 2018
-
Meet Manuel Cobos, transplant surgeon and researcher
Follow Dr. Cobos as he works to provide a patient with a new liver and performs surgery using a tiny video camera.
-
Media ReleaseNovartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine preventionPatients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…
-
Quest for a new measure of mental health
Novartis researchers are searching for more effective ways to discover drugs for neurological and psychiatric diseases.
-
Media ReleaseSandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is…
-
Media ReleaseNovartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanomaPhase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with…
-
Media ReleaseNovartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver flukeNovartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million…
-
Media ReleaseNovartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitisNovartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to…
-
Media ReleaseNovartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal womenKisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
-
Featured NewsNovartis Financial Results – Q2 2018Today, Novartis announced the company’s financial results for the second quarter and H1 of 2018.
-
Key ReleaseNovartis erzielt im zweiten Quartal ein solides Wachstum und setzt die Transformation zu einem fokussierten Arzneimittelunternehmen fortDer Nettoumsatz steigt um 5% (kWk[1], +7% USD), vor allem dank folgender Beiträge: Cosentyx erreicht USD 701 Millionen (+40% kWk) mit starken Zuwächsen bei allen Indikationen in den USA und der…
Pagination
- ‹ Previous page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- …
- 150
- › Next page